BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery
This study has been completed.
Sponsor:
Boehringer Ingelheim Pharmaceuticals
Information provided by:
Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01225822
First received: October 20, 2010
Last updated: May 23, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of this study is to establish the dose-response relationship with regard to efficacy and safety of BIBR 1048 (50 mg bis in die(b.i.d), 150 mg b.i.d, 225 mg b.i.d. and 300 mg quaque die(q.d) ) in preventing venous thromboembolism(VTE) in patients undergoing primary elective total hip and knee replacement.
| Condition | Intervention | Phase |
|---|---|---|
|
Venous Thromboembolism |
Drug: Enoxaparin Drug: BIBR 1048 |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Prevention |
| Official Title: | BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery |
Resource links provided by NLM:
Drug Information available for:
Dabigatran
Dabigatran etexilate
Enoxaparin sodium
Dabigatran etexilate mesylate
U.S. FDA Resources
Further study details as provided by Boehringer Ingelheim Pharmaceuticals:
Primary Outcome Measures:
- Number of Participants With Venous Thromboembolic (VTE) Events [ Time Frame: Treatment period (up to day 8+/-2 days visit) ] [ Designated as safety issue: No ]Deep vein thrombosis (DVT) (proximal and distal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic DVT confirmed by venography during the treatment period or PE confirmed by objective testing
Secondary Outcome Measures:
- Number of Participants With VTE Events and All Cause Mortality [ Time Frame: Treatment period (up to day 8+/-2 days visit) ] [ Designated as safety issue: No ]Deep venous thrombosis (DVT) (proximal and distal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic DVT confirmed by venography during the treatment period or Pulmonary Embolism (PE) confirmed by objective testing and all deaths.
- Number of Participants With Proximal DVT, PE (Pulmonary Embolism) and VTE Related Mortality [ Time Frame: Treatment period (up to day 10) ] [ Designated as safety issue: No ]Deep venous thrombosis (DVT) (proximal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic proximal DVT confirmed by venography during the treatment period or PE confirmed by objective testing plus VTE related mortality
- Number of Participants With Proximal DVT [ Time Frame: Treatment period (up to day 8+/-2 days visit) ] [ Designated as safety issue: No ]Deep venous thrombosis (DVT) (proximal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic proximal DVT confirmed by venography during the treatment period
- Number of Participants With Major Bleeding Events (MBE) [ Time Frame: From approximately 14 days prior to surgery to 4-6 weeks post surgery ] [ Designated as safety issue: Yes ]
| Enrollment: | 1973 |
| Study Start Date: | November 2002 |
| Primary Completion Date: | August 2003 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: BIBR 1048 50 mg bis in die(b.i.d)
BIBR 1048 50 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus one placebo matching enoxaparin 0 mg once a day for the treatment period
|
Drug: BIBR 1048
50 mg b.i.d BIBR 1048 capsule twice a day for 5-10 days of treatment period
|
|
Experimental: BIBR 1048 150 mg b.i.d
BIBR 1048 150 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
|
Drug: BIBR 1048
150 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
|
|
Experimental: BIBR 1048 225 mg b.i.d
BIBR 1048 225 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
|
Drug: BIBR 1048
225 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
|
|
Experimental: BIBR 1048 300 mg quaque die(q.d)
BIBR 1048 150 mg q.d once a day plus placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
|
Drug: BIBR 1048
300 mg q.d BIBR 1048 capsule for 5-10 treatment period
|
|
Active Comparator: Enoxaparin 40 mg subcutaneous(s.c)
placebo matching BIBR 1048 0 mg twice a day plus enoxaparin 40 mg s.c once a day for the treatment period
|
Drug: Enoxaparin
Enoxaparin 40 mg s.c once a day for 5-10 days of treatment period
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria
- Patients scheduled to undergo a primary elective total hip or knee replacement.
- Male of female being 18 years or older.
- Patients weighing at least 40 kg.
- Written informed consent for study participation.
Exclusion criteria
- Bleeding diathesis, constitutional or acquired coagulation disorders.
- Major surgery or trauma(e.g., hip fracture) within the last 3 months.
- Cardiovascular disease
- Any history of haemorrhagic stroke, intracranial or intraocular bleeding or cerebral ischaemic attacks lasting more than 24 hours and / or with cardiovascular pathological findings.
- Deep vein thrombosis(DVT), gastrointestinal or pulmonary bleeding, gastric or duodenal ulcer within the last year.
- History of or acute intracranial disease
- Liver disease
- Renal disease
- Use of long-term anticoagulants or antiplatelet drugs within 7 days prior to hip/knee replacement operation.
- Pre-menopausal women who are not surgically steriles, are nursing and are of child-bearing potential and are not practising acceptable methods of birth control
- Known allergy to contrast media
- Thrombocytopenia
- Allergy against heparin.
- Active malignant disease or current cytostatic treatment.
- Treatment with an investigational drug in the past month.
- Leg amputee
- Known alcohol or drug abuse
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01225822
Hide Study Locations
Hide Study LocationsLocations
| Austria | |
| 1160.19.43004 Krankenhaus der Barmherzigen Schwestern Linz | |
| Linz, Austria | |
| 1160.19.43002 Orthopädisches Spital Speising | |
| Wien, Austria | |
| 1160.19.43001 A.ö. Krankenhaus d. Statutarstadt Wiener Neustadt | |
| Wr. Neustadt, Austria | |
| Belgium | |
| 1160.19.32002 V.U.B. Jette | |
| Brussel, Belgium | |
| 1160.19.32004 UZ Gent | |
| Gent, Belgium | |
| 1160.19.32005 Virga Jesseziekenhuis | |
| Gent, Belgium | |
| 1160.19.32006 Boehringer Ingelheim Investigational Site | |
| Huy, Belgium | |
| 1160.19.32007 C.H.U. de Tivoli | |
| La Louvière, Belgium | |
| Czech Republic | |
| 1160.19.42004 University Hospital Brno | |
| Brno-Bohunice, Czech Republic | |
| 1160.19.42001 Hospital Kladno | |
| Kladno, Czech Republic | |
| 1160.19.42006 Hospital Mlada Boleslav | |
| Mlada Boleslav, Czech Republic | |
| 1160.19.42003 University Hospital Ostrava | |
| Ostrava, Czech Republic | |
| 1160.19.42005 University Hospital Plzen | |
| Plzen, Czech Republic | |
| 1160.19.42009 University Hospital Na Bulovce | |
| Prague 8, Czech Republic | |
| Denmark | |
| 1160.19.45042 Orthopedic Surgical Clinic | |
| Frederiksberg, Denmark | |
| 1160.19.45045 Gentofte Hospital | |
| Hellerup, Denmark | |
| 1160.19.45043 Herlev Hospital | |
| Herlev, Denmark | |
| 1160.19.45041 Hørsholm Sygehus | |
| Hørsholm, Denmark | |
| 1160.19.45044 Orthopedic Surgical Dept. | |
| Silkeborg, Denmark | |
| Finland | |
| 1160.19.35802 Keski-Suomen keskussairaala | |
| Jyväskylä, Finland | |
| 1160.19.35801 Oulun yliopistollinen sairaala, Leikkaus- ja tehohoidon yks. | |
| Oulu, Finland | |
| France | |
| 1160.19.33004 Div | |
| Illkirch cedex, France | |
| 1160.19.33007 Clinique du Mail | |
| La Rochelle, France | |
| 1160.19.33009 Hôpital Edouard Herriot | |
| Lyon cedex 03, France | |
| 1160.19.33006 Clinique Mutualiste | |
| Saint-Etienne cedex 2, France | |
| 1160.19.33008 Clinique de l'Atlantique | |
| St Herblain cedex, France | |
| Hungary | |
| 1160.19.36003 Sándor Péterfy Hospital | |
| Budapest, Hungary | |
| 1160.19.36001 Kálmán Pándy County Hospital | |
| Gyula, Hungary | |
| 1160.19.36004 Bács-Kiskun County Hospital | |
| Kecskemét, Hungary | |
| 1160.19.36002 Albert Szent-Györgyi Medical and Pharmacological Center | |
| Szeged, Hungary | |
| 1160.19.36005 Szent György Hospital | |
| Székesfehérvár, Hungary | |
| Italy | |
| 1160.19.39003 U. O. Ortopedia e Traumatologia | |
| Bergamo, Italy | |
| 1160.19.39005 Modulo Coordinazione Dipartimentale di Ricerca e Anestesia | |
| Bologna, Italy | |
| 1160.19.39002 Fondazione Centro S. Raffaele | |
| Milano, Italy | |
| 1160.19.39001 IRCCS Policlinico San Matteo | |
| Pavia, Italy | |
| 1160.19.39004 Ospedale di Circolo di Varese | |
| Varese, Italy | |
| Netherlands | |
| 1160.19.31001 Boehringer Ingelheim Investigational Site | |
| Amsterdam, Netherlands | |
| 1160.19.31003 Boehringer Ingelheim Investigational Site | |
| Hilversum, Netherlands | |
| 1160.19.31005 Hengstdal 3 | |
| Nijmegen, Netherlands | |
| 1160.19.31006 Boehringer Ingelheim Investigational Site | |
| Sittard, Netherlands | |
| 1160.19.31004 Boehringer Ingelheim Investigational Site | |
| Zwolle, Netherlands | |
| Norway | |
| 1160.19.47001 Nordlandssykehuset HF, Bodø | |
| Bodø, Norway | |
| 1160.19.47004 Martina Hansens Hospital | |
| Bærum Postterminal, Norway | |
| 1160.19.47008 Martina Hansens Hospital | |
| Bærum Postterminal, Norway | |
| 1160.19.47007 Sykehuset Innlandet HF, Avd. Elverum | |
| Elverum, Norway | |
| 1160.19.47005 Haugesund sjukehus HF | |
| Haugesund, Norway | |
| 1160.19.47002 Sykehuset Telemark HF, Avd. Skien | |
| Skien, Norway | |
| 1160.19.47003 Helse Sunnmøre HF, Ålesund sykehus | |
| Ålesund, Norway | |
| South Africa | |
| 1160.19.27002 Suite 203 | |
| Johannesburg, South Africa | |
| 1160.19.27001 Dept. of Haematology | |
| Johannesburg, South Africa | |
| Sweden | |
| 1160.19.46002 Kirurgavdelningen | |
| Falköping, Sweden | |
| 1160.19.46001 | |
| Göteborg, Sweden | |
| 1160.19.46004 Ortopediska kliniken, Länssjukhuset, Halmstad | |
| Halmstad, Sweden | |
| 1160.19.46003 Ortopediska kliniken, Länssjukhuset i Kalmar | |
| Kalmar, Sweden | |
| 1160.19.46007 Kungälvs sjukhus | |
| Kungälvs, Sweden | |
| 1160.19.46005 Kirurg Ortopediska kliniken, Sjukhuset i Lidköping | |
| Lidköping, Sweden | |
| 1160.19.46008 Ortopediska Institutionen | |
| Linköping, Sweden | |
| 1160.19.46009 Sahlgrenska Universitetssjukhuset, Mölndal | |
| Mölndal, Sweden | |
| 1160.19.46006 Boehringer Ingelheim Investigational Site | |
| Varberg, Sweden | |
Sponsors and Collaborators
Boehringer Ingelheim Pharmaceuticals
Investigators
| Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim Pharmaceuticals |
More Information
Additional Information:
Related Info 
Related Info 
No publications provided
| Responsible Party: | Boehringer Ingelheim, Study Chair, Boehringer Ingelheim |
| ClinicalTrials.gov Identifier: | NCT01225822 History of Changes |
| Other Study ID Numbers: | 1160.19 |
| Study First Received: | October 20, 2010 |
| Results First Received: | November 18, 2010 |
| Last Updated: | May 23, 2012 |
| Health Authority: | Austria: Belgium: Czech Republic: Denmark: Finland: France: Hungary: Italy: Ethics Committee Netherlands: Norway: South Africa: Sweden: |
Additional relevant MeSH terms:
|
Thromboembolism Venous Thromboembolism Venous Thrombosis Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Thrombosis Enoxaparin |
Anticoagulants Hematologic Agents Therapeutic Uses Pharmacologic Actions Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Cardiovascular Agents |
ClinicalTrials.gov processed this record on June 17, 2013